☰

Kerry O. Cresawn, Ph.D.

Affiliations: 
2004 University of Florida, Gainesville, Gainesville, FL, United States 
Area:
Genetics, Immunology, Animal Physiology Biology, Pathology
Google:
"Kerry Cresawn"
Tree Publications Grants Similar researchers PubMed Report error

Parents

Sign in to add mentor
Barry J. Byrne grad student 2004 UF Gainesville
 (Liver-directed strategies and immunologic consequences of recombinant AAV -mediated cross -correction of glycogen storage disease type II.)

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Mah CS, Falk DJ, Germain SA, et al. (2010) Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 502-10
Mah C, Pacak CA, Cresawn KO, et al. (2007) Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 501-7
Mah C, Pacak CA, Cresawn KO, et al. (2006) 410. Physiological Correction of Glycogen Storage Disease Type II Using Adeno-Associated Virus Serotype 1 Vectors Molecular Therapy. 13
Pacak CA, Mah C, Cresawn KO, et al. (2006) 28. rAAV2/9 Mediated Gene Delivery of Acid α-Glucosidase Corrects the Cardiac Phenotype in a Mouse Model of Pompe Disease Molecular Therapy. 13: S12
Mah C, Cresawn KO, Fraites TJ, et al. (2005) Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors Gene Therapy. 12: 1405-1409
Cresawn KO, Fraites TJ, Wasserfall C, et al. (2005) Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid α-glucosidase in a model of glycogen storage disease type II Human Gene Therapy. 16: 68-80
Cresawn KO, Mah CS, Zolotukhin I, et al. (2005) 911. Comparison of rAAV Serotype, Promoter, and Treatment Age for the Correction of Glycogen Storage Disease Type II Molecular Therapy. 11
Cresawn KO, Mah CS, Fraites TJ, et al. (2005) 909. Sustained Correction of Glycogen Storage Disease Type II by rAAV1 Vector-Mediated Gene Therapy Molecular Therapy. 11
Mah C, Cresawn KO, DeRuisseau LR, et al. (2005) 354. Correction of Respiratory Function by Recombinant AAV1 Mediated Gene Therapy in a Murine Model of Glycogen Storage Disease Type II Molecular Therapy. 11
Mah C, Fraites TJ, Cresawn KO, et al. (2004) A new method for recombinant adeno-associated virus vector delivery to murine diaphragm. Molecular Therapy : the Journal of the American Society of Gene Therapy. 9: 458-63
See more...